These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1402643)

  • 1. Does graft-violates-host disease give a better indication of what goes on than graft-versus-host disease?
    Stavem P; Harboe M
    J Intern Med; 1992 Oct; 232(4):372. PubMed ID: 1402643
    [No Abstract]   [Full Text] [Related]  

  • 2. Human graft-versus-host disease.
    Parkman R
    Immunodefic Rev; 1991; 2(4):253-64. PubMed ID: 2059433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-host disease in the 21st century: new perspectives on an old problem.
    Ferrara JL; Levine JE
    Semin Hematol; 2006 Jan; 43(1):1-2. PubMed ID: 16412783
    [No Abstract]   [Full Text] [Related]  

  • 5. Obstructive airways disease: a rare but serious manifestation of chronic graft-versus-host disease, after allogeneic marrow transplantation in humans.
    Atkinson K; Bryant D; Biggs J; Concannon A; Dodds A
    Transplant Proc; 1984 Aug; 16(4):1030-3. PubMed ID: 6380052
    [No Abstract]   [Full Text] [Related]  

  • 6. Temporal discordance between graft-versus-leukemia and graft-versus-host responses: a strategy for the separation of graft-versus-leukemia/graft-versus-host reactivity?
    Hari P; Logan B; Drobyski WR
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):743-7. PubMed ID: 15505605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies.
    Ferrara JL; Yanik G
    Clin Adv Hematol Oncol; 2005 May; 3(5):415-9, 428. PubMed ID: 16167015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and functions of inflammatory cells isolated from acute graft-versus-host disease target organs after bone marrow transplantation in the rat.
    Renkonen R; Leszczynski D; Wangel A; Häyry P
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2689. PubMed ID: 3274579
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic graft-versus-host disease following allogeneic peripheral blood and bone marrow stem cell transplants: a single center experience.
    Takami A; Ishiyama K; Asakura H; Shiobara S; Nakao S
    Haematologica; 2002 Jun; 87(6):664-6. PubMed ID: 12031928
    [No Abstract]   [Full Text] [Related]  

  • 10. Objective monitoring of graft-versus-host disease: alpha 1-antichymotrypsin concentration changes after bone marrow transplantation in patients developing graft-versus-host reactions.
    Kamiguchi H; Ohkubo T; Yamamura M; Katsunuma T
    Tokai J Exp Clin Med; 1985 Jun; 10(2-3):165-8. PubMed ID: 3914740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis and pathology of graft-vs.-host disease.
    Wagner JE; Vogelsang GB; Beschorner WE
    Am J Pediatr Hematol Oncol; 1989; 11(2):196-212. PubMed ID: 2665549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of cytokines during the course of graft-versus-host disease following bone marrow transplantation: a case report.
    Takatsuka H; Takemoto Y; Okada M; Sawada A; Katsuno T; Wada H; Kakishita E
    Cytokine; 2000 Aug; 12(8):1225-7. PubMed ID: 10930300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
    Liu YP; Li Z; Nador RG; Strober S
    Transplantation; 2008 Feb; 85(4):607-14. PubMed ID: 18347541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late development of graft-versus-host disease in an autologous BMT recipient.
    Appleton AL; Sviland L; Wilkes J; Pearson AD; Malcolm AJ
    Bone Marrow Transplant; 1994 Jun; 13(6):823-5. PubMed ID: 7920321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation.
    Peralvo J; Bacigalupo A; Pittaluga PA; Occhini D; Van Lint MT; Frassoni F; Nardelli E; Transino A; Pantarotto M; Marmout AM
    Bone Marrow Transplant; 1987 Oct; 2(3):279-85. PubMed ID: 3332176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-versus-leukemia without graft-versus-host disease: an elusive goal of bone marrow transplantation.
    Champlin R
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):46-52. PubMed ID: 1509294
    [No Abstract]   [Full Text] [Related]  

  • 18. Effector cells of graft-versus-host disease, host resistance, and the graft-versus-leukemia effect: summary of a workshop on bone marrow transplantation.
    Ringdén O; Deeg HJ; Beschorner W; Slavin S
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2758-61. PubMed ID: 3547953
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.
    Truog AW; Wozniak SP
    Oncol Nurs Forum; 1990; 17(1):39-44. PubMed ID: 2405360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Graft vs host disease].
    Moalic V; Ferec C
    Pathol Biol (Paris); 2006 May; 54(5):304-8. PubMed ID: 16530350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.